Genetic Signatures Ltd has released a press release.
STI Detection Kit Clinical Validation Trial Results
Filed with ASX ·
Watch Genetic Signatures' latest callGenetic Signatures (ASX:GSS) Q4 2026 Earnings Call · Replay · Aug 25Read the transcript of Genetic Signatures (ASX:GSS) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Genetic Signatures Ltd. on 6ix
In the deck
Earlier from Genetic Signatures
- Open Briefing - Capital Raising and Company Outlook
- Clinical Validation of Sexual Health Detection Kit Commenced
- Completion of $14m capital raising
- UCLA to launch Genetic Signatures technology
- GSS launches Analyte Specific Reagents in US
Later from Genetic Signatures
- 2016 AGM MD and CEO Presentation
- Appendix 4D - Half Yearly Report and Accounts
- GSS Launches Sexually Transmitted Infection (STI) Kit
- Results of Flavivirus Clinical Trial
- Regulatory and Patent approval
Follow Genetic Signatures into a list and get an email when it puts out news.
Follow Genetic Signatures